<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00155246</url>
  </required_header>
  <id_info>
    <org_study_id>930202</org_study_id>
    <nct_id>NCT00155246</nct_id>
  </id_info>
  <brief_title>Efficacy of Pentoxifylline on Chronic Kidney Disease</brief_title>
  <official_title>Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study whether pentoxifylline has additive renoprotective effect in patients taking ARB&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with CKD and serum creatinine 1.3~6.0 md/gl, having taken losartan 100 mg/day for&#xD;
      at least 3 months, with stable renal function, will be recruited to a randomized open-label&#xD;
      trial. Patients taking pentoxifylline or not will be compared for their spot urinary&#xD;
      proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine&#xD;
      ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone&#xD;
      concentration between groups in a 2-year study. Add-on pentoxifylline in control group in the&#xD;
      same dose as in treat group will be performed to observe the renoprotective effect if any&#xD;
      protective potential is demonstrated in the end of maintenance 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>spot urinary proteinuria between groups</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups.</measure>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pentoxifylline (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to pentoxifylline&#xD;
&#xD;
          -  Females are nursing or pregnant&#xD;
&#xD;
          -  Obstructive uropathy&#xD;
&#xD;
          -  Unable to stop chronic immunosuppressive therapy, NSAID&#xD;
&#xD;
          -  Congestive heart failure (New York Heart Association functional class III or IV)&#xD;
&#xD;
          -  Unstable angina, myocardial infarction, coronary artery bypass graft surgery,&#xD;
             percutaneous coronary intervention, within the past 6 months prior to signing the&#xD;
             informed consent form&#xD;
&#xD;
          -  Cerebral hemorrhage within the past 6 months prior to signing the informed consent&#xD;
             form&#xD;
&#xD;
          -  Retinal hemorrhage within the past 6 months prior to signing the informed consent form&#xD;
&#xD;
          -  Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular&#xD;
             hypertension, pheochromocytoma)&#xD;
&#xD;
          -  Severe uncontrolled hypertension with SBP &gt; 220 mmHg and/or DBP &gt; 115 mmHg&#xD;
&#xD;
          -  Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST &gt; 2&#xD;
             times the upper limit of the normal range&#xD;
&#xD;
          -  Biliary obstructive disorders (e.g. cholestasis)&#xD;
&#xD;
          -  Active malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tun-Jun Tsai, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hosptial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 27, 2010</last_update_submitted>
  <last_update_submitted_qc>January 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shuei-Liong Lin/Attending Physician</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>CKD, pentoxifylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

